API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
https://www.prnewswire.com/news-releases/calliditas-receives-notice-of-allowance-for-united-states-patent-application-covering-setanaxib-in-cancer-treatment-302110166.html
https://www.prnewswire.com/news-releases/european-medicines-agency-committee-for-orphan-medicinal-products-provides-positive-opinion-on-calliditas-application-for-setanaxib-in-alport-syndrome-301948139.html
https://www.prnewswire.com/news-releases/calliditas-therapeutics-granted-orphan-drug-designation-by-the-fda-for-the-treatment-of-alport-syndrome-with-setanaxib-301940809.html
https://www.prnewswire.com/news-releases/calliditas-announces-supportive-interim-data-from-phase-2-head-and-neck-cancer-trial-with-lead-nox-inhibitor-candidate-setanaxib-301876307.html
https://www.prnewswire.com/news-releases/first-patient-randomized-in-pivotal-transform-study-with-setanaxib-301482346.html
https://www.prnewswire.com/news-releases/positive-phase-1-results-in-high-dose-setanaxib-trial-301209899.html
https://www.businesswire.com/news/home/20210117005066/en/Genkyotex-announces-positive-Phase-1-results-demonstrating-a-favorable-safety-and-pharmacokinetic-profile-of-high-dose-setanaxib